Search

Displaying results 3071 - 3080 of 7540 in total
  1. Drug

    Clopamide

    go.drugbank.com/drugs/DB13792
    Investigational

    Like thiazide diuretics, it has an aromatic sulfonamide base but with no double-ring structure.

  2. Drug

    Volixibat

    go.drugbank.com/drugs/DB13914
    Investigational

    According to Shire, the pharmaceutical manufacturer of Volixibat, it has been granted fast track status by the Food and Drug Administration due to promising initial results and a need for therapeutic treatments … Volixibat is a selective inhibitor of the apical sodium-dependent bile acid transporter (ASBT), a transmembrane protein primarily expressed by enterocytes of the ileum.

  3. Drug

    Dapoxetine

    go.drugbank.com/drugs/DB04884
    Investigational

    In a phase II proof-of-concept study conducted by PPD, dapoxetine demonstrated a statistically significant increase in ejaculatory latency when compared to placebo. … In October 2005, the company received a FDA Non-Approvable letter from the FDA, at which time they planned to work with regulators to address outstanding questions.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  4. Drug

    Reboxetine

    go.drugbank.com/drugs/DB00234
    ApprovedInvestigationalWithdrawn

    Reboxetine has two chiral centers, but it only exists as two enantiomers, (R,R)-(-)- and (S,S)-(+)-reboxetine.

  5. Target

    Immunoglobulin heavy variable 3-30

    go.drugbank.com/bio_entities/BE0004312
    TargetHumans

    V region of the variable domain of immunoglobulin heavy chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocy...

    Synonyms: Ig heavy chain V-III region BUR
  6. Drug

    Ibrutinib

    go.drugbank.com/drugs/DB09053
    ApprovedInvestigational

    [L45894] Ibrutinib was approved by the EMA in October 2014 [L45884] and by Health Canada in November 2014. … [A32299] Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval;[L12228] however, in

  7. Drug

    Etrolizumab

    go.drugbank.com/drugs/DB12189
    Investigational

    Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, is typified by a chronic gastrointestinal inflammatory microenvironment, driven in part by the excessive infiltration … [A244564, A244569, A244579, A244584] A recent class of drugs designed to impair lymphocyte homing, so-called "anti-trafficking agents" (ATAs), have shown some success and include approved drugs such as

  8. Drug

    Quinacrine

    go.drugbank.com/drugs/DB01103
    Investigational

    An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years.

    Synonyms: N4-(6-chloro-2-methoxy-9-acridinyl)-N1,N1-diethyl-1,4-pentanediamine
  9. Drug

    Acrivastine

    go.drugbank.com/drugs/DB09488
    Approved

    As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension

    Categories: Histamine H1 Antagonists, Non-Sedating
  10. Drug

    Chlorphentermine

    go.drugbank.com/drugs/DB01556
    ApprovedIllicitWithdrawn

    It has properties similar to those of dextroamphetamine. It has been implicated in lipid storage disorders and pulmonary hypertension. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1223)

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome